Men benefit more than women from nicotine replacement therapy for smoking cessation because nicotine affects a key neuroreceptor differently in the two sexes, a NIDA-sponsored study suggests. The findings highlight the need for alternative therapies for women smokers, and point to the female hormone progesterone as a potential therapeutic target.
Marijuana-dependent outpatients who were treated with the medication gabapentin in a pilot clinical trial reduced their cannabis use more and reported fewer symptoms of drug withdrawal than patients who received a placebo.
Several factors contribute to treatment professionals’ stress and burnout, including how much influence they feel they have in their organization and their caseload. Surprisingly, a NIDA-supported study found that the link between staff stress and burnout was weaker in programs with higher patient caseloads than those with lower caseloads. In addition, program administrators can help counselors reduce their stress by giving them a voice in organizational policies and procedures.
Clinical trials of N-acetylcysteine to help people recovering from drug abuse avoid relapse have demonstrated only moderate efficacy. New NIDA-supported research shows that while a low dose of the medication activates receptors associated with lowered drug-seeking behavior, a higher dose appears to activate receptors associated with increased drug-seeking behavior. The result suggests that a medication or combination of medications that stimulate the receptor GluR2/3 and block mGluR5 may work better than N-acetylcysteine alone.
Methadone treatment centers are not foci for serious criminal activity, according to a study that used crime reports and global positioning data to compare crime rates at various distances around methadone centers, hospitals, convenience stores, and residential neighborhoods.
NIDA-funded researchers have gathered evidence that brief interventions can help adolescents move away from drug use. In a clinical trial, middle and high school students markedly reduced their substance use following two 60-minute sessions that combined motivational interviewing and cognitive behavioral therapy.
The immune system has an extraordinary ability to recognize compounds foreign to the body and eliminate them. NIDA-sponsored scientists are working to harness this ability to create vaccines that will protect individuals against the psychogenic and addictive effects of abused drugs. This animation shows one of the most promising strategies, which has already yielded partial success in producing effective vaccines against nicotine, cocaine, and other drugs.
Researchers report a significant advance in the search for medications that can suppress pain but avoid opioids’ abuse potential and other undesirable CNS effects. A new compound reduces mouse responses in animal models of neurogenic and chronic inflammatory (e.g., arthritic) pain. The compound, called UB937, enhances the natural pain-killing activity of the neurotransmitter anandamide, and exerts its analgesic effects entirely in peripheral tissues, without entering the brain.
New vaccines that aim to promote recovery from cocaine and heroin abuse showed promise in animal testing. Both vaccines induced rats’ immune system to produce high titers of antibodies that inhibit the target drug from reaching the brain. The rats’ behaviors when given access to the target drug indicated that the vaccines reduced the reinforcing effects that, in recovering people, can cause lapses to turn into relapses.